Sector intelligence and perspective
June 20, 2018
I’d be halving or turning a profit from some positions
A short-term outlook won’t go away. It’s about
Being responsive to the “happenings” of our sector, hope for a cure is a reason to invest but, not a financial metric
Corporate seats: Alnylam Pharmaceuticals (ALNY) appointed two new executives, Masako Nakamura as Senior Vice President, Head of Asia, and Jing L. Marantz, M.D., Ph.D., as Senior Vice President, Head of Medical Affairs.
Pre-open indications: 4 SELLs and 1 BUY
When RMi is right more than many times about “our” sector pricing and first in news; it just confirms why one should subscribe to understand how today’s pre-open indications shed light on share pricing!
June 18, 2018
For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed, gene and cell therapy sector, click on the button below:
http://www.regmedinvestors.com/create-account
Why spend time searching for sector news and analytics … it’s all right here!
Review daily indicators – pre-open and close, trends – whether they’re your friend or not, advance/decline lines of 45 covered companies, volatility responses followed by the factors involving decliners versus gainers and their daily percentages.
I “never leave an investor uninformed”
June 19, 2018
The path is clear …
Hold, buy or sell – I recommend profiting in an uncertain and tentative market
Pre-open indications: 3 HITs and 1 MISS (1 by pennies and sold into end of session strength with profit). Right again as gene editing stocks - CRSP (-$0.57), NTLA ($0.00) fumbled even with patent award and EDIT (+$0.16) rose feebly after yesterday’s warning
Out and about: Stories of the day and a few of yesterday’s heroes – SLDB (+13.62 or +46.36%) jumps, CLBS (+$2.68 or +67.34%) on news, BSTG is also up on what (? - my opinion which scam Ponzi, pyramid or both) as ATHX (-$0.25) continues its decline
Of the 45 covered the 19 downside equities finished in a range of -$0.01 to -$1.61 with biggest bottoms of -$ and $ and $ while the 24 upside equities oscillated from +$0.04 to $1.78 with toppers of $13.62, $6.19, $4.00 and $3.55 with 2 flat closes
Let the analytics, trend lines, patterns and “count” speak - be a subscriber! I’m also still waiting for someone else to have a daily view – RMi is it!
June 19, 2018
CLBS closed down -$0.12 and is up in the pre-market +$1.00 or +25.32% - BUY
June 18, 2018
VSTM’s shares up +$1.379 or +21.13% at the open - SELL on the dramtic incline
June 18, 2018
SLDB closed up +$1.81 on Friday and is up +$2.70 or +10.19% in the pre-market The clinical hold was imposed in March and came after the unexpected hospitalization of a patient in the P1/2 trial, called Ignite DMD.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
